← All Signals

🏥 FDA: CareFusion 213, LLC — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-05-26Date

Summary

A second sterility issue with BD PurPrep applicators from the same facility amplifies quality control concerns for Becton Dickinson. This pattern suggests systemic manufacturing problems, increasing the likelihood of regulatory action and customer attrition.

Actionable: Reduce positions in Becton Dickinson and evaluate competitors in the antiseptic market.

AI Confidence: 90%

Data Points

firmCareFusion 213, LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productBD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 25x26mL Applicators per carton. Caref

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now